Wegovy and Ozempic contain the same active ingredient, semaglutide. Their weekly injections have different FDA-approved uses and dosing limits [3] [4]. Both brands also have daily tablets with separate dosing instructions. The FDA approved Ozempic as the new name for one Rybelsus tablet formulation [3] [9]. The dose and price comparisons below cover injections.
What each injection is approved for
Ozempic injection improves blood sugar in adults with type 2 diabetes. It also reduces the risk of cardiovascular death, nonfatal heart attack and nonfatal stroke in adults with type 2 diabetes and established cardiovascular disease. In adults with type 2 diabetes and chronic kidney disease it reduces the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death [4].
Wegovy injection is approved for long-term weight reduction in adults and adolescents aged 12 and older with obesity, and in adults with overweight and at least one weight-related condition. It also reduces the risk of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. A separate accelerated approval covers adults with noncirrhotic MASH and stage F2–F3 liver fibrosis[3].
A plan’s GLP-1 coverage rules can depend on both the drug and the reason it was prescribed. Benefits, eligibility criteria and prior authorization can differ across plans. For people on Medicare, Medicare’s Ozempic and Wegovy rules explain how coverage can vary by indication. The two injections should not be combined under Wegovy’s prescribing information [3].
How the injection doses differ
Both injections start at 0.25 mg weekly for four weeks. Ozempic then moves to 0.5 mg, with increases to 1 mg and 2 mg if further blood sugar control is needed after at least four weeks at the preceding dose. The recommended maintenance dose for its kidney indication is 1 mg weekly [4].
Wegovy increases through 0.5 mg, 1 mg and 1.7 mg. For adult weight reduction, maintenance is 1.7 mg or 2.4 mg weekly, with 2.4 mg recommended. The 7.2 mg Wegovy HD option is for adults who tolerate 2.4 mg for at least four weeks and for whom further weight reduction is clinically indicated [3].
What trials in adults with diabetes showed
STEP 2 assigned 1,210 adults with type 2 diabetes and overweight or obesity to weekly semaglutide at 2.4 mg, 1 mg or placebo for 68 weeks. Estimated weight change was −9.6% with 2.4 mg and −3.4% with placebo. Gastrointestinal side effects occurred in 63.5% of the 2.4 mg group, 57.5% of the 1 mg group and 34.3% of the placebo group, and were mostly mild or moderate [1].
SUSTAIN FORTE assigned 961 adults with type 2 diabetes to 2 mg or 1 mg for 40 weeks. In the analysis that included outcomes regardless of whether participants stopped treatment or needed rescue medication, HbA1c fell by 2.1 versus 1.9 percentage points. Weight fell by 6.4 versus 5.6 kg, a difference whose confidence interval included zero. Gastrointestinal side effects occurred in 34% versus 31% [2].
What Novo Nordisk lists for the injections
On November 14, 2026, Novo Nordisk listed Ozempic injection at $1,027.51 per pen and standard Wegovy injection at $1,349.02 per package [5] [6]. For its savings offers, NovoCare defines a monthly supply as one Ozempic pen or one package of four Wegovy single-dose pens [7] [8].
NovoCare’s published standard self-pay rates were $349 per month for Ozempic at 0.25 mg, 0.5 mg or 1 mg and $499 for 2 mg. The corresponding Wegovy prices were $349 for 0.25 mg through 2.4 mg and $399 for 7.2 mg. NovoCare also advertised $199 for up to two eligible starter fills at 0.25 mg or 0.5 mg for patients new to its program. For home delivery, the prescription must be written and received by December 31, 2026 and shipped by January 31, 2027[7] [8].
Our guide to semaglutide prices explains how list prices, cash offers and insurance can produce different bills. Check the current offer terms for eligibility and confirm the quoted price for the dose and package on the prescription.